Impli

Impli is a biotech company that specializes in implantable subdermal hormone monitoring platforms, primarily aimed at enhancing women's fertility treatments, particularly in vitro fertilization (IVF). Founded in 2019 by Anna Luisa Schaffgotsch in London and later expanding to Lucerne, Switzerland, Impli develops innovative sensors the size of a grain of rice. These sensors enable real-time hormone monitoring through a mobile application using NFC-enabled smartphones. The flagship product, known as ImpliCaspian, is designed to assist women undergoing IVF by providing continuous hormonal profiles without the need for frequent blood draws. This device, expected to launch in the U.S. in 2027, is worn for a typical 30-day IVF cycle and removed afterward. Impli's technology aims to improve treatment personalization, optimize medication dosages, and enhance the overall success rates of fertility treatments. The company collaborates with fertility clinics and healthcare providers, offering a less invasive and more convenient alternative to traditional monitoring methods.

• Employees 13
• Founded 2019